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Introduction
Mitoxantrone (MX) is an anthracenedione derivative that in-
tercalates into DNA, inhibits topoisomerase II, and causes 
strand breaks that can result in chromosomal translocations.1 
The results of a pivotal placebo-controlled, double-blinded, 
randomized, multicenter MX trial by the Mitoxantrone in 
Multiple Sclerosis Study Group (MIMS) about 10 years ago 
opened up a treatment option for patients suffering from high-
ly active forms of relapsing-remitting multiple sclerosis (MS) 
(RRMS) and secondary progressive MS (SPMS).2 MX has 
therefore been used as an escalating immunotherapy in MS. 
Due to its approval and its promising results concerning dis-
ability and relapses among MS patients, as well as there being 
few alternative strategies available for SPMS, the number of 
patients receiving MX has increased in the last decade.
However, the MX lifetime dosage is limited by its potential 
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Background and PurposezzThe aim of this study was to elucidate the role of therapy-related 
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tential predictors for individual risk assessment.
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disease, treatment, and follow-up data were collected from hospital records. Patients regularly 
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therapy was 4.1% (26 patients) among all patients. Analyses of the risk for cardiotoxicity re-
vealed that cumulative dose exposure was the only statistically relevant risk factor associated 
with cardiac dysfunction.
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maximum recommended cumulative dose is higher than was initially assumed. Interestingly, a 
subgroup of patients was identified who experienced cardiac dysfunction shortly after initiation 
of mitoxantrone and who received a low cumulative dose. Therefore, each administration of 
mitoxantrone should include monitoring of cardiac function to enhance the treatment safety for 
patients and to allow for early detection of any side effects, especially in potential high-risk 
subgroups (as determined genetically). J Clin Neurol 2014;10(4):289-295
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toxicity, and in particular its cardiac and hematologic adverse 
reactions. In oncologic indications, MX-associated congestive 
heart failure (CHF) was reported in 2.6–6% of patients who 
received MX doses of up to 140 mg/m2 body surface area 
(BSA).3,4 The cardiotoxicity of the anthracycline family is 
considered to be dose-dependent and to result in myocardial 
damage that reduces the left ventricular ejection fraction 
(LVEF). In rare but potentially severe cases, cardiotoxicity re-
sults in CHF and other heart dysfunctions such as electrocar-
diogram (ECG) changes, arrhythmias, and clinical heart fail-
ure.5 Data on MX-related cardiotoxicity in MS are sparse, 
with the incident rate of symptomatic heart failure ranging be-
tween 0.2% and 2.0% for symptomatic heart failure.6-11 We 
have reported previously the occurrence of LVEF reduction in 
4 out of 18 prospectively assessed patients at a very early stage 
of MX treatment.12 At present, the risk factors contributing to 
MX-related cardiotoxicity are not completely understood. This 
study was therefore performed to assess cardiac dysfunction 
subsequent to MX treatment in a large German cohort of MS 
patients, and to identify potential clinical predictors for indi-
vidual risk assessment.
Methods
Within a multicenter retrospective cohort study performed at 
two MS centers (Departments of Neurology at the University 
Medical Centers at Mainz and Bochum) between 1995 and 
2010, we collected data for 639 German MS patients treated 
with at least one infusion of MX, and analyzed the cardiac 
side effects attributed to MX. Patients diagnosed with worsen-
ing RRMS, SPMS, or primary progressive MS according to 
the current diagnostic criteria regularly received intravenous 
MX infusions every 3 months at a dose of 12 mg/m2 BSA per 
infusion, based on the MIMS protocol. Individualized dose 
adaptation by leukocyte nadirs was commonly performed. Pa-
tients were evaluated medically before treatment initiation, in-
cluding an assessment of their scores on the Expanded Dis-
ability Status Scale (EDSS).
No patients experienced cardiac dysfunction before MX 
treatment. All new cardiac adverse events during treatment–
including reduction of resting LVEF measured using transtho-
racic echocardiogram (<50% or an absolute reduction of 
≥10% from the baseline), diastolic and systolic contraction 
abnormalities, and newly emerging arrhythmias that could not 
be attributed to any other origin–were regarded as therapy-re-
lated cardiac dysfunction. Both the clinical diagnosis and 
transthoracic echocardiography (TTE) were evaluated by a 
cardiologist. Assessments of LVEF and CHF by clinical exami-
nation, and ECG and TTE were performed at baseline and 
then annually after discontinuation or completion of the treat-
ment, as recommended by the guidelines for the diagnosis and 
treatment of neurological diseases by the German Society of 
Neurology. During the treatment phase, the frequency of car-
diac check-ups varied slightly between the patients: a TTE 
check-up was performed before each infusion in patients who 
had received MX in recent years, and biannually in patients 
who had received MX less recently. This slight discrepancy 
was due to changes associated with continuous reevaluations 
of guidelines concerning the monitoring of patients under MX 
treatment over the course of our relatively long observational 
period (1995–2012). The treatment was stopped when any type 
of cardiac dysfunction as described above was diagnosed.
Mean values and standard deviations are given for the de-
scriptive analyses, in addition to the median with the 25th and 
75th percentiles for the cumulative MX dose. Differences be-
tween two groups were assessed using the nonparametric two-
tailed Mann-Whitney U test. Fisher’s exact test was used to 
evaluate the effects of gender and disease course.
Logistic regression modeling was used to determine the sig-
nificance of the effects of potential contributing factors (cumu-
lative dose, age at initial diagnosis, EDSS score, gender, and 
disease course) on cardiotoxicity risk. The odds ratios are pre-
sented with 95% confidence intervals.
Since this was an explorative study, no adjustments for mul-
tiple testing were performed. The statistical tests were con-
ducted for illustrative purposes rather than for hypothesis test-
ing. Probability values are given for descriptive reasons only, 
and should be interpreted with caution and in connection with 
effect estimates.
All statistical analyses were performed using SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA), and the local ethics com-
mittees at the two involved centers approved the final protocol.
Results
We identified 639 MX-treated MS patients (400 females, 239 
males) in the databases of the 2 university medical centers. 
Their mean age was 36.1 years (range, 21–74 years), and 102 
had RRMS, 441 had SPMS, and 96 had primary progressive 
multiple sclerosis. Patients received a mean cumulative MX 
dose of 65.8 mg/m² BSA, and 19.4% received more than 100 
mg/m2 BSA (maximum, 184 mg/m2 BSA). The median cumu-
lative dose was 60.0 mg/m2 BSA (25th percentile, 36.0 mg/m2; 
75th percentile, 90.0 mg/m2). The mean baseline EDSS score 
was 5.6 (range, 2.0–8.5). The demographics and characteris-
tics of the patients in this cohort are presented in Table 1.
Subclinical cardiac dysfunction was recorded for 26 of the 
639 patients (4.1%) during the observation period. Among 
these, eight patients (1.25%) had an LVEF that had decreased 
below 50%, and nine patients (1.41%) exhibited an absolute 
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LVEF reduction of ≥10% from the baseline. Nine additional 
cardiac-related adverse events were observed: arrhythmia (four 
patients, 0.63%), systolic dysfunction (three patients, 0.47%), 
diastolic relaxation dysfunction (one patient, 0.15%), and peri-
cardial effusion (one patient, 0.15%). None of the patients in 
our cohort developed symptomatic CHF. The cumulative dose 
Table 2. Characteristics of patients with cardiac dysfunction attributed to MX treatment
Patient no. Medical center Gender
Age at initial 
diagnosis (years)
Cumulative dose 
(mg/m² BSA)
Adverse heart condition
1 Mainz Female 33 87 Reduced cardiac contraction
2 Mainz Male 65 97 Hypokinesis, reduced LVEF (>10%)
3 Mainz Male 55 122 Reduced LVEF (35%)
4 Mainz Female 27 135 Reduced LVEF (>10%)
5 Mainz Female 28 130 Reduced LVEF (49%)
6 Mainz Female 31 84 Arrhythmia
7 Mainz Female 31 98 Diastolic relaxation dysfunction
8 Mainz Female 38 108 Arrhythmia
9 Mainz Female 48 140 Arrhythmia
10 Mainz Female 33 184 Reduced LVEF (49%)
11 Mainz Female 46 108 Reduced LVEF (42%)
12 Mainz Male 28 141 Hypokinesis, systolic dysfunction
13 Bochum Male 35 46 Reduced LVEF (>10%)
14 Bochum Female 27 51.2 Reduced LVEF (>10%)
15 Bochum Female 74 65 Reduced LVEF (44%)
16 Bochum Male 40 105 Reduced LVEF (44%)
17 Bochum Female 36 114 Right heart dysfunction
18 Bochum Female 29 12 Reduced LVEF (>10%)
19 Bochum Male 32 57 Reduced LVEF (>10%)
20 Bochum Female 23 81.5 Reduced LVEF (>10%)
21 Bochum Female 57 35 Pericardial effusion
22 Bochum Male 23 12 Reduced LVEF (>10%)
23 Bochum Male 54 24.5 Reduced LVEF (45%)
24 Bochum Male 29 75 Reduced LVEF (45%)
25 Bochum Female 27 49 Hypokinesis, reduced LVEF (>10%)
26 Bochum Female 23 28 Arrhythmia
BSA: body surface area, LVEF: left ventricular ejection fraction, MX: mitoxantrone.
Table 1. Descriptive statistics of the study cohort
Parameter All patients from Mainz and Bochum (n=639)
Gender 400 (63%) female
239 (37%) male
Clinical course RRMS: 102 (16%)
SPMS: 441 (69%)
PPMS: 96 (15%)
Age at initial MS diagnosis
Age at MX initiation
Disease duration to MX initiation
36.1±11.4 years
44.1 years
8.0 years
EDSS score 5.6±1.5
Mean cumulative dose of MX 65.8±38.0 mg/m2 BSA
Median cumulative dose of MX 60.0 mg/m2 BSA (25th percentile, 36.0 mg/m2 BSA; 
  75th percentile, 90.0 mg/m2 BSA)
Follow up since last MX cycle 1.36 years
Adverse heart condition 26 (4.1%)
Data are mean±SD or (%) values. 
BSA: body surface area, EDSS: Expanded Disability Status Scale, MS: multiple sclerosis, MX: mitoxantrone, PPMS: primary progressive 
multiple sclerosis, RRMS: relapsing-remitting multiple sclerosis, SPMS: secondary progressive multiple sclerosis.
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in patients with cardiac dysfunction varied between 12 and 
184 mg/m² BSA (mean, 84.2 mg/m² BSA). Interestingly, de-
layed cardiac dysfunction occurred in one patient 6 months af-
ter treatment completion (reported hypokinesis and systolic 
dysfunction). The characteristics of patients with cardiac dys-
function are summarized in Table 2.
We examined the potential relationships between cardiotox-
icity and clinical or demographic risk factors in our cohort. 
The mean cumulative dose was significantly higher in patients 
with cardiac dysfunction (n=26, 84.2 mg/m2 BSA) than in those 
without cardiac events (n=613, 64.9 mg/m2 BSA, p=0.0262) 
(Fig. 1). There was a statistically significant dose dependency 
when the cumulative dose was analyzed as a dichotomous co-
variate. Among patients with cardiac events, 15 (57.2%) re-
ceived doses of >80 mg/m2 BSA, compared to 11 patients 
(42.3%) who received ≤80 mg/m2 BSA (p=0.0064). The inci-
dence of cardiac dysfunction was 8.19% in patients receiving 
a cumulative dose of >80 mg/m2 BSA compared to 2.75% in 
patients receiving a cumulative dose of ≤80 mg/m2 BSA.
Furthermore, stepwise backward and forward logistic re-
gression revealed that cumulative-dose exposure is the only 
statistically relevant risk factor associated with the risk of car-
diac dysfunction (p=0.003). We concluded that the odds of 
cardiac dysfunction were 1.019 times higher for every mg/m2 
BSA increase in MX cumulative dose, and that the 95% confi-
dence interval for the odds ratio was 1.006–1.032 (Table 3). 
Fig. 2A illustrates the proportion of patients without cardiac 
dysfunction over the observational period in years as a Ka-
plan-Meier curve. Fig. 2B demonstrates the relationship be-
tween the incidence of cardiac dysfunction and cumulative 
dose. Interestingly, albeit at a lower incidence, cardiac dysfunc-
tion seems to occur shortly after initiation of MX and when re-
ceiving a low cumulative dose (10–30 mg/m2 BSA) in suscep-
tible individuals.
We did not identify a statistically significant association be-
tween gender, age at initial diagnosis, disability (EDSS score) 
or disease course, and the occurrence of cardiac events (Table 
Table 3. Results of the logistic regression analysis
Parameter p Odds ratio
95% confidence interval
Lower limit Upper limit
Cumulative 
  MX dose
0.003 1.019 1.006 1.032
Gender 0.272 0.511 0.155 1.691
Age at initial  
  diagnosis
0.879 1.004 0.955 1.056
EDSS score 0.571 1.134 0.734 1.754
RRMS (reference) 0.631
SPMS (vs. RRMS) 0.429 0.485 0.080 2.918
PPMS (vs. RRMS) 0.828 0.786 0.090 6.887
EDSS: Expanded Disability Status Scale, MX: mitoxantrone, 
PPMS: primary progressive multiple sclerosis, RRMS: relapsing-
remitting multiple sclerosis, SPMS: secondary progressive multi-
ple sclerosis.
Fig. 1. Analyses of potential relationships between the occurrence of cardiac events and patient characteristics. The cumulative dose was 
significantly higher in the patients group with cardiac events. No significant difference was observed between gender, age at initial diagno-
sis, disability before MX treatment or disease course, and the incidence of cardiac events. Data are mean and SEM values; *p<0.05. BSA: 
body surface area, EDSS: Expanded Disability Status Scale, MX: mitoxantrone, PPMS: primary progressive multiple sclerosis, RRMS: re-
lapsing-remitting multiple sclerosis, SPMS: secondary progressive multiple sclerosis.
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3, Fig. 1).
Seventeen of the 26 patients with cardiac dysfunction at-
tended a clinical follow-up at least once following the initial 
detection of a cardiac event. We observed a transient cardiac 
dysfunction within 6 of these patients and persistent dysfunc-
tion in the other 11. The remaining nine patients either were 
lost to follow-up or could not be evaluated after discontinua-
tion because the end of the observational period was less than 
1 year after the last MX cycle.
Discussion
The benefit of MX as an escalation therapy for worsening 
RRMS and SPMS has been demonstrated in clinical trials.2,13 
The restriction of a cumulative lifetime dosage of MX accounts 
for potential risks of treatment. Dose dependency is widely ac-
cepted, and particularly in terms of cardiotoxicity, although 
there are reports of patients with cardiac failure following low-
dose treatment.12,14 The mechanisms of MX-associated car-
diotoxicity are not completely understood, but mediation of 
myocardial tissue damage via interactions with cellular iron 
metabolism leading to formation of reactive oxygen has been 
suggested.15
The overall incidence of cardiac dysfunction in our study 
cohort (4.1%), as measured by cardiac echo and/or ECG, was 
higher than that found in the initial phase II and phase III MX 
clinical trials,2,16 but comparable to the range of other postmar-
keting studies. In a prospective French study, 4.9% of 802 pa-
tients presented with decreased LVEF.8 In the prospective 
Registry to Evaluate Novantrone Effects in Worsening Mul-
tiple Sclerosis study involving 509 patients, a reduction of 
LVEF was observed in 5.3% during the treatment phase and 
5.6% during the follow-up phase.7
A retrospective analysis of 1,378 MS patients reported a re-
duction of LVEF in 1.8% of patients receiving cumulative dos-
es of <100 mg/m2 BSA versus 5% of those receiving doses of 
>100 mg/m2 BSA.6 In our cohort the incidence of cardiac dys-
function was significantly higher in patients receiving a cumu-
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lative dose of >80 mg/m2 BSA (8.19%) than in those receiving 
a cumulative dose of >80 mg/m2 BSA (2.75%). Interestingly, 
albeit at a lower incidence, we observed cardiac dysfunction 
shortly after initiation of MX in the low-cumulative-dose 
groups, indicating that there may be a subgroup of susceptible 
individuals. This is in line with our previously reported reduc-
tion of LVEF in 4 out of 18 prospectively assessed MS patients 
very early in the MX treatment course.12,14
The reasons for early cardiac dysfunction in our cohort re-
main unclear, and so we are currently evaluating potential 
pharmacogenetic markers. None of our patients had a history 
of cardiac disease. Speculation has arisen as to whether early 
cardiotoxicity provides evidence of a dose-independent cross-
reaction with the myocardium. The observed early change in 
LVEF might be effectively clinically compensated during first-
treatment courses, although a subclinical decline in cardiac 
dysfunction or a temporary reduction of the LVEF might be 
appear transiently.
With regard to the parameters assessed herein, we did not 
identify a statistically significant association between gender, 
age at initial diagnosis, disease duration, disability (EDSS 
score), or disease course, and the occurrence of cardiac events. 
As reported previously, none of these indicators can be regard-
ed as prognostic factors for MX-associated cardiac dysfunc-
tion.6,10 This highlights the need to identify pharmacogenetic 
biomarkers that allow individualized risk stratification. In this 
context, it has recently been reported that the bioactivation of 
MX mediated through CYP2E1 metabolism, which occurs lo-
cally in the cardiomyoblasts, plays a significant role in the cel-
lular damage promoted by MX.17 Thus, cytochrome P450 poly-
morphisms might contribute to individual susceptibility to 
MX-induced cardiotoxicity. Furthermore, the relevance of 
ABC-transporter gene polymorphisms as potential pharmaco-
genetic markers for MX response and its cardiotoxicity in MS 
has been demonstrated.18 These potential pharmacogenetic risk 
factors are currently being investigated in prospective stud-
ies.19,20
Despite our large cohort, the present data must be interpret-
ed with caution due to the use of a retrospective approach over 
different observation periods. In addition, the mean follow-up 
period was too short to comprehensively detect delayed MX-
related cardiotoxicity, some of which might have developed 
after treatment discontinuation. However, two recent prospec-
tive studies have demonstrated a cardiotoxicity incidence sim-
ilar to that reported here.7,8
Notwithstanding the above-mentioned limitation, the data 
reported here demonstrate that MX therapy in MS patients is 
associated with cardiotoxicity that is dose-dependent, but can 
occur very early in susceptible individuals. Since reliable 
markers for predicting the individual susceptibility to MX-in-
duced cardiotoxicity are not yet available, cautious reevalua-
tion of treatment indications should be performed regularly 
during the treatment course, and physicians should use the 
lowest possible cumulative dose that achieves the desired clin-
ical effect. Studies have demonstrated a concomitant cardio-
protective effect of dexrazoxane in combination with MX, but 
thus far this has not influenced the treatment recommenda-
tion.21,22 Nonetheless, treatment recommendations have nar-
rowed the indications for MX treatment from the beginning 
for SPMS, progressive relapsing MS, or worsening RRMS, 
since the initial trials have been restricted to this cohort of pa-
tients.
We emphasize the importance of vigilant monitoring of pa-
tients for cardiac complications by assessment of cardiac signs 
and symptoms by history, physical examination, ECG, and 
TTE before the administration of each dose of MX, and then 
annually for up to 5 years following the cessation of treatment 
conducted according to the recommendations of the United 
States Food and Drug Administration published in 2008.23
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